Cargando…

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

BACKGROUND: The leucine rich repeat containing 3B (LRRC3B) gene is a tumor suppressor gene involved in the anti-tumor immune microenvironment. Expression of LRRC3B and DNA methylation at the LRRC3B promoter region may serve as a useful marker to predict response to anti-PD-1 therapy. However, no stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Linfeng, Fu, Sha, Du, Wei, He, Li-na, Zhang, Xuanye, Wang, Yixing, Zhou, Yixin, Hong, Shaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928207/ https://www.ncbi.nlm.nih.gov/pubmed/36798137 http://dx.doi.org/10.3389/fimmu.2023.959868

Ejemplares similares

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma
por: Zhang, Xuanye, et al.
Publicado: (2022)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy
por: Li, Anlin, et al.
Publicado: (2023)

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy
por: He, Li-Na, et al.
Publicado: (2023)

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
por: Zhang, Xuanye, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy
por: Wang, Yixing, et al.
Publicado: (2021)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Novel Therapy for Glioblastoma Multiforme by Restoring LRRC4 in Tumor Cells: LRRC4 Inhibits Tumor-Infitrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing Exosomes
por: Li, Peiyao, et al.
Publicado: (2017)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
por: Geng, Suxia, et al.
Publicado: (2022)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
por: Yuan, Shumin, et al.
Publicado: (2020)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy
por: Chu, Xiao-Dong, et al.
Publicado: (2022)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation
por: Green, Jack P, et al.
Publicado: (2020)

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
por: Carbone, Maria Luigia, et al.
Publicado: (2023)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas
por: Zhang, Zuping, et al.
Publicado: (2008)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Yan, Zheng, et al.
Publicado: (2021)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
por: Yin, Li, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
por: Tezera, Liku B, et al.
Publicado: (2020)

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy
por: McPherson, Rhoanne C, et al.
Publicado: (2014)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dofq3bv05vlqoc3ukpbv43qhmh